Anthelminthic drugs: evolution of approaches and current WHO recommendations

Helminthiases remain a significant global health issue, affecting billions of people. The increase in the introduction of tropical parasitic diseases into non-endemic regions, as well as the potential development of resistance to existing drugs, highlight the need to update knowledge and adapt treatment strategies. Objective: to present a systematized literature review on the effectiveness of anthelmintics. Methods: a review of modern domestic and foreign literature was carried out, the search was carried out using the keywords «treatment of helminthiasis», «treatment of nematodes», «treatment of trematodes», «treatment of cestodes» using the databases PubMed, Scopus, and the scientific library eLibrary.RU. Results: information on the main anthelmintic drugs is presented, the advantages and limitations of combination treatment regimens are considered, modern WHO recommendations for the treatment of various helminthiasis are summarized, and a summary table is presented with an overview of the drugs used to treat helminthiasis, indicating their spectrum of action and effectiveness. Conclusions: current approaches to helminthiasis treatment are characterized by a shift from narrowly focused methods to integrated strategies that include a combination of individual treatment with mass preventive measures. Despite the advances made, it is necessary to continue monitoring the susceptibility of helminths to drugs and adapt treatment regimens in a timely manner to effectively control the spread of parasitic diseases.

1. Tigabu A., Taye S., Aynalem M., Adane K. Prevalence and associated factors of intestinal parasitic infections among patients attending Shahura Health Center, Northwest Ethiopia. BMC Res Notes. 2019; 12(1):333. doi:10.1186/s13104-019-4377-y

2. Rospotrebnadzor news 03/31/2021 «About the most common helminths that are transmitted through food» https://www.rospotrebnadzor.ru/documents (In Russ.)

3. Bronstein A.M., Malyshev N.A., Zharov S.N., Luchshev V.I., Rakhimova O.Yu., Legonkov Yu.A. First experience with combined therapy for loiasis in a Russian tourist visiting Equatorial Guinea. Epidemiologiya i infektsionnye bolezni=Epidemiology and Infectious Diseases. 2012; 17(4):32—35. (In Russ.) https://doi.org/10.17816/2072-3117-2012-4-32-35.

4. Bronshtejn A.M., Malyshev N.A., Zharov S.N. Ostryj mochepolovoj shistosomoz u turista, posetivshego Ugandu (klinicheskoe opisanie sluchaya i obzor literatury) Epidemiologiya i infekcionnye bolezni=Epidemiology and Infectious Diseases. 2012; 5:47—50. (In Russ.).

5. Kozlovsky A. Helminthic and Protozoal Diseases in Children: A Literature Review. Pediatrics. Eastern Europe. 2024; 12(3):496—509. (In Russ.). doi.org/10.34883/PI.2024.12.3.012

6. Buonfrate D., Salas-Coronas J., Muñoz J., Maruri B.T., et al. Multiple-dose versus single-dose ivermectin for Strongyloides stercoralis infection (Strong Treat 1 to 4): a multicentre, open-label, phase 3, randomised controlled superiority trial. Lancet Infect Dis. 2019 Nov; 19(11):1181—1190. doi: 10.1016/S1473-3099(19)30289-0.

7. Gandasegui J., Onwuchekwa C., Krolewiecki A.J., Doyle S.R., Pullan R.L., Enbiale W., Kepha S., Hatherell H.A., van Lieshout L., Cambra-Pellejà M., Escola V., Muñoz J. Ivermectin and albendazole coadministration: opportunities for strongyloidiasis control. Lancet Infect Dis. 2022 Nov; 22(11): e341—e347. doi: 10.1016/S1473-3099(22)00369-3.

8. Palmeirim M.S., Hürlimann E., Knopp S., Speich B., Belizario V. Jr., Joseph S.A., Vaillant M., Olliaro P., Keiser J. Efficacy and safety of co-administered ivermectin plus albendazole for treating soil-transmitted helminths: A systematic review, meta-analysis and individual patient data analysis. PLoS Negl Trop Dis. 2018 Apr 27; 12(4):e0006458. doi: 10.1371/journal.pntd.0006458.

9. Moser W., Schindler C., Keiser J. Drug Combinations Against Soil-Transmitted Helminth Infections. Adv Parasitol. 2019; 103:91—115. doi:10.1016/bs.apar.2018.08.002

10. Wu V.C., Huang J.W., Lien H.C., Hsieh S.T., Liu H.M., Yang C.C., Lin Y.H., Hwang J.J., Wu K.D. Levamisole-induced multifocal inflammatory leukoencephalopathy: clinical characteristics, outcome, and impact of treatment in 31 patients. Medicine (Baltimore). 2006 Jul; 85(4):203—213. doi: 10.1097/01.md.0000230250.95281.60.

11. Yan R., Wu Q., Ren J., Cui H., Zhai K., Zhai Z., Duan Q. Clinical features and magnetic resonance image analysis of 15 cases of demyelinating leukoencephalopathy induced by levamisole. Exp Ther Med. 2013 Jul; 6(1):71—74. doi: 10.3892/etm.2013.1077.

12. Barda B., Ame S.M., Ali S.M., Albonico M., Puchkov M., Huwyler J., Hattendorf J., Keiser J. Efficacy and tolerability of moxidectin alone and in coadministration with albendazole and tribendimidine versus albendazole plus oxantel pamoate against Trichuris trichiura infections: a randomised, non-inferiority, single-blind trial. Lancet Infect Dis. 2018 Aug;18(8):864—873. doi: 10.1016/S1473-3099(18)30233-0.

13. Keller L., Palmeirim M.S., Ame S.M., Ali S.M., Puchkov M., Huwyler J., Hattendorf J., Keiser J. Efficacy and Safety of Ascending Dosages of Moxidectin and Moxidectin-albendazole Against Trichuris trichiura in Adolescents: A Randomized Controlled Trial. Clin Infect Dis. 2020 Mar 3; 70(6):1193— 1201. doi: 10.1093/cid/ciz326.

14. Tan B., Opoku N., Attah S.K., Awadzi K., Kuesel A.C., Lazdins-Helds J., Rayner C., Ryg-Cornejo V., Sullivan M., Fleckenstein L. Pharmacokinetics of oral moxidectin in individuals with Onchocerca volvulus infection. PLoS Negl Trop Dis. 2022 Mar 25; 16(3):e0010005. doi: 10.1371/journal.pntd.0010005.

15. Hofmann D., Sayasone S., Sengngam K., Chongvilay B., Hattendorf J., Keiser J. Efficacy and safety of ascending doses of moxidectin against Strongyloides stercoralis infections in adults: a randomised, parallel-group, single-blinded, placebo-controlled, dose-ranging, phase 2a trial. Lancet Infect Dis. 2021; 21(8):1151—1160. doi:10.1016/S1473-3099(20)30691-5

16. Henriquez-Camacho C., Gotuzzo E., Echevarria J., White A.C. Jr., Terashima A., Samalvides F., Pérez-Molina J.A., Plana M.N. Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection. Cochrane Database Syst Rev. 2016 Jan 18; 2016(1):CD007745. doi: 10.1002/14651858.CD007745.pub3.

17. Jittamala P., Monteiro W., Smit M.R., Pedrique B., et al. A systematic review and an individual patient data meta-analysis of ivermectin use in children weighing less than fifteen kilograms: Is it time to reconsider the current contraindication? PLoS Negl Trop Dis. 2023 Jan 6;1 7(1):e0011053. doi: 10.1371/journal.pntd.0011053.

18. A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 Years. https://clinicaltrials.gov/

19. Tripathi B., Roy N., Dhingra N. Introduction of Triple-Drug Therapy for Accelerating Lymphatic Filariasis Elimination in India: Lessons Learned. Am J Trop Med Hyg. 2022; 106(5_Suppl):29—38. doi:10.4269/ajtmh.21-0964

20. News release 14 June 2018 of World Health Organization https://tdr.who.int/

21. Townson S., Tagboto S., McGarry H.F., Egerton G.L., Taylor M.J. Onchocerca parasites and Wolbachia endosymbionts: evaluation of a spectrum of antibiotic types for activity against Onchocerca gutturosa in vitro. Filaria J. 2006; 5:4. doi:10.1186/1475-2883-5-4

22. Gardon J., Gardon-Wendel N., Demanga-Ngangue, Kamgno J., Chippaux J.P., Boussinesq M. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet. 1997; 350(9070):18—22. doi:10.1016/S0140-6736(96)11094-1

23. Garcia H.H., Gonzales I., Lescano A.G., Bustos J.A.,et al. Cysticercosis Working Group in Peru. Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial. Lancet Infect Dis. 2014 Aug;1 4(8):687—695. doi: 10.1016/S1473-3099(14)70779-0.

24. Brunetti E., Kern P., Vuitton D.A.; Writing Panel for the WHO-IWGE. Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Trop. 2010; 114(1):1—16. doi:10.1016/j.actatropica.2009.11.001

25. Wen H., Vuitton L., Tuxun T., Li J., Vuitton D.A., Zhang W., McManus D.P. Echinococcosis: Advances in the 21st Century. Clin Microbiol Rev. 2019 Feb 13; 32(2):e00075-18. doi: 10.1128/CMR.00075-18.

26. Respondek A., Baaryła M., Popławska-Ferenc A., Kosieradzki M., Dybicz M., Gołębiowski M., Tronina O., Rahnama M., Karpeta E., Małkowski P. Echinococcosis of the liver in Poland — review of the literature and our own clinical material. Clin Exp Hepatol. 2024 Sep; 10(3):150—158. doi: 10.5114/ceh.2024.141698.

27. Qian M-B., Keiser J., Utzinger J., Zhou X-N. Clonorchiasis and opisthorchiasis: epidemiology, transmission, clinical features, morbidity, diagnosis, treatment, and control. Clin Microbiol Rev. 2024; 37(1):e0000923. doi:10.1128/cmr.00009-23

28. Qian M.B., Yap P., Yang Y.C., Liang H., Jiang Z.H., Li W., Tan Y.G., Zhou H., Utzinger J., Zhou X.N., Keiser J. Efficacy and safety of tribendimidine against Clonorchis sinensis. Clin Infect Dis. 2013 Apr; 56(7):e76—82. doi: 10.1093/cid/cis1011.

29. Gandhi P., Schmitt E.K., Chen C.W., Samantray S., Venishetty V.K., Hughes D. Triclabendazole in the treatment of human fascioliasis: a review. Trans R Soc Trop Med Hyg. 2019; 113(12):797—804. doi:10.1093/trstmh/trz093

30. Guideline for the control and elimination of human schistosomiasis. 22 February 2022. https://www.who.int